Idarubicina

Idarubicina Uses, Dosage, Side Effects, Food Interaction and all others data.

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Idarubicina is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicina may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicina possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Idarubicina
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Idarubicina
Availability	Prescription only
Generic	Idarubicin
Idarubicin Other Names	4-Demethoxydaunorubicin, Idarubicin, Idarubicina, Idarubicine, Idarubicinum
Related Drugs	Venclexta, prednisone, methotrexate, dexamethasone, triamcinolone, Decadron, Keytruda, hydroxyurea, pembrolizumab, vincristine
Type
Formula	C₂₆H₂₇NO₉
Weight	Average: 497.4939 Monoisotopic: 497.168581467
Protein binding	97%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Idarubicina is an anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults.

For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Idarubicina is also used to associated treatment for these conditions: Acute Myeloid Leukemia (AML)

How Idarubicina works

Idarubicina has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicina forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.